文献速递静脉血栓栓塞

预测下腔静脉滤器安全性和有效性研究:独特临床实践研究设计

Predicting the Safety and Effectiveness of Inferior Vena Cava Filters Study: Design of a unique safety and effectiveness study of inferior vena cava filters in clinical practice.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2019-10-18

PRESERVE研究由血管外科学会、介入放射学会、美国FDA及多家滤器制造商共同实施,旨在了解下腔静脉滤器真实世界使用的安全性、有效性和模式。计划纳入约2100例患者(每种滤器品牌300例),在60个美国中心招募,评估放置指征、品牌、并发症、稳定性、回收频率及临床有效性。主要安全终点为穿孔、栓塞、血栓形成、复发性DVT及严重不良事件的复合终点。

要点

  • PRESERVE研究纳入7家制造商的多种下腔静脉滤器,计划每种品牌300例,共约2100例。
  • 主要安全终点为穿孔、栓塞、血栓形成、复发性DVT及严重不良事件的复合终点。
  • 随访包括出院、3、6、12、18、24个月及回收后1个月,影像学评估滤器稳定性。

核心结论

  • PRESERVE研究是迄今最大的前瞻性研究,旨在调查当代下腔静脉滤器真实世界结局,以期改善患者护理。

研究设计与样本

  • 由血管外科学会、介入放射学会、美国FDA及多家滤器制造商实施的前瞻性研究。
  • 计划在60个美国中心纳入约2100例患者(每种滤器品牌300例),年龄≥18岁需下腔静脉滤器预防静脉血栓栓塞且无造影剂过敏并愿意遵守随访。
  • 纳入7家制造商的滤器:ALN(ALN±hook)、Argon(Option Elite)、B.Braun(LP、Vena Tech Convertible)、CR Bard(Denali)、Cook(Gunther Tulip)、Cordis(OptEase、TrapEase)、Philips Volcano(Crux)。

关键数值与推荐

  • 主要安全终点为复合临床终点,包括无穿孔、栓塞、血栓形成、复发性DVT及定义的严重不良事件。
  • 次要终点包括3个月时机械稳定性和手术相关并发症、6/12/18/24个月时主要不良事件、以及任何时间点滤器倾斜>15°。
  • 随访于出院、3、6、12、18、24个月及/或回收后1个月(以先发生者为准)评估。
  • 放置前后行血管内超声或静脉造影,3个月行腹部平片,12和24个月行增强CT评估滤器稳定性。

临床怎么用

  • 研究将记录滤器放置指征、品牌、并发症、稳定性、回收频率和成功率及每种滤器的临床有效性,为临床实践提供真实世界证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Death from venous thromboembolism remains a significant cause of death worldwide. Although anticoagulation is the cornerstone of treatment in patients at risk for venous thromboembolism, inferior vena cava (IVC) filter use has increased exponentially over the last decade driven predominantly by the prophylactic use in patients at risk for venous thromboembolism despite limited evidence supporting this practice. The Predicting the Safety and Effectiveness of Inferior Vena Cava Filters (PRESERVE) Study is being implemented by the Society for Vascular Surgery, Society of Interventional Radiology, U.S. Food and Drug Administration, and several IVC filter manufactures to better understand the safety, effectiveness, and current patterns of real-world use of IVC filters. METHODS: The PRESERVE Study includes IVC filters from seven manufacturers: ALN (ALN ± hook), Argon (Option Elite), B. Braun (LP, Vena Tech Convertible), CR Bard (Denali), Cook (Gunther Tulip), Cordis (OptEase, TrapEase), and Philips Volcano (Crux). The indications for filter placement, filter brand, complications, stability, frequency and success of retrieval, and clinical effectiveness of each filter will be recorded. Approximately 2100 patients (300 for each filter brand included in the study) are intended to be enrolled at 60 U.S. centers. RESULTS: Men and women age 18 years or older requiring IVC filters for prevention of venous thromboembolism will be included in the study if no contrast allergy is present and they are willing to commit to the prescribed study follow-up. Participants will be evaluated at discharge, 3, 6, 12, 18, and 24 months after filter placement and/or 1 month after retrieval, which ever occurs first. Intravascular ultrasound examination or venography will be done before and after IVC filter placement, with abdominal plain film at 3 months, and contrast enhanced computed tomography scans at 12 and 24 months to evaluate filter stability. The primary safety end point is a composite of clinical end points, including freedom from perforation, embolization, thrombosis, recurrent DVT, and defined serious adverse events. Secondary end points include mechanical stability and procedure related complications at 3 months, major adverse events at 6, 12, 18, and 24 months, and filter tilt of more than 15° at any point. CONCLUSIONS: The PRESERVE Study represents the largest prospective study ever undertaken to investigate real-world outcomes with contemporary use of IVC filters. The investigators await results with the hope that it can improve patient care.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Gillespie DL, Spies JB, Siami FS, et al. Predicting the Safety and Effectiveness of Inferior Vena Cava Filters Study: Design of a unique safety and effectiveness study of inferior vena cava filters in clinical practice. J Vasc Surg Venous Lymphat Disord. 2019. PMID: 31636051. doi:10.1016/j.jvsv.2019.07.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。